Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPERA-T Study
NCT05238116Phase 3Terminated
- Sponsor
- Pulmocide
- Start
- Jun 2022
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 20
01
Overview
A Phase 3 trial of opelconazole in Invasive Pulmonary Aspergillosis (IPA), sponsored by Pulmocide. Started Jun 2022; status: terminated.
02
Drugs
opelconazole
03
Conditions
Invasive Pulmonary Aspergillosis (IPA)
Beyond the preview
Go deeper on NCT05238116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238116.